新型无创纤维化评分在MASLD中的风险分层
该前瞻性队列研究纳入马来西亚和香港两个中心683例活检确诊的MASLD患者,中位随访9.7年,评估MAFLD纤维化评分(MFS)预测肝脏相关事件和死亡风险。高危组(MFS≥15)肝脏相关事件和全因死亡风险显著高于低危组,MFS预测15年肝脏相关事件的AUC为0.916,优于其他无创评分包括瞬时弹性成像。
要点
- MFS≥15高危组肝脏相关事件风险是低危组的9.90倍,全因死亡风险是4.13倍
- MFS预测15年肝脏相关事件AUC为0.916,全因死亡AUC为0.698,优于其他无创评分
- MFS≥15预测肝脏相关事件敏感性77.2%、特异性94.3%,预测死亡敏感性41.4%、特异性94.8%
核心结论
- MFS能有效对MASLD患者进行风险分层,识别长期肝脏相关事件和死亡高风险人群。
研究设计与样本
- 前瞻性队列研究,纳入马来西亚和香港2个三级中心683例活检确诊的MASLD患者,中位随访9.7年。
主要发现
- 高危组(MFS≥15)肝脏相关事件发生率为844/10万人年(95%CI 436-1475),低危组为75/10万人年(95%CI 21-193)。
- 高危组全因死亡率发生率为1532/10万人年(95%CI 948-2341),低危组为383/10万人年(95%CI 234-592)。
- 高危组较低危组肝脏相关事件风险比9.90(95%CI 3.19-30.76),全因死亡风险比4.13(95%CI 2.22-7.69)。
- MFS预测15年肝脏相关事件AUC为0.916,全因死亡AUC为0.698,优于其他无创评分包括瞬时弹性成像。
- MFS≥15预测肝脏相关事件敏感性77.2%、特异性94.3%;预测死亡敏感性41.4%、特异性94.8%。
关键数值与推荐
- MFS低危定义为<15,高危定义为≥15。
- MFS≥15预测肝脏相关事件敏感性77.2%、特异性94.3%,预测死亡敏感性41.4%、特异性94.8%。
临床怎么用
- 可利用常规临床数据计算MFS,以MFS≥15识别MASLD中肝脏相关事件和死亡高风险患者,便于早期干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) may identify high-risk groups for early intervention to reduce liver-related complications. We examined the prognostic accuracy of the MAFLD fibrosis score (MFS) in predicting risks of liver-related events and mortality among patients with MASLD. METHODS: This prospective cohort study with a median follow-up period of 9.7 years included 683 patients with biopsy-proven MASLD at 2 tertiary centers in Malaysia and Hong Kong. Noninvasive scores, including MFS, were computed using routine clinical data. Cumulative incidences of any liver-related events and all-cause mortality were compared between patients at low (MFS <15) and high risk (MFS ≥15) with Kaplan-Meier estimation and Cox regression. RESULTS: With mean age 52.0 ± 11.8 years and 53.0% male, the high-risk group had an incidence of liver-related events of 844 (95% confidence interval [CI], 436-1475) and all-cause mortality of 1532 (95% CI, 948-2341), compared with 75 (95% CI, 21-193) and 383 (95% CI, 234-592) per 100,000 person-years in the low-risk group, respectively. The hazard ratios were 9.90 (95% CI, 3.19-30.76) for liver-related events and 4.13 (95% CI, 2.22-7.69) for all-cause mortality. MFS outperformed other noninvasive scores, including vibration-controlled transient elastography, in predicting liver-related events and all-cause mortality at 15-year follow-up (area under receiver operating characteristic curve 0.916 and 0.698). A single cutoff of MFS≥15 demonstrated sensitivity of 77.2% and specificity of 94.3% in predicting liver-related events and 41.4% and 94.8% in predicting mortality. CONCLUSIONS: MFS optimally stratifies patients with MASLD with high risk for developing long-term liver-related events and mortality.
引用
- Cheung JTK, Zhang X, Wong GL, et al. Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 41654153. doi:10.1016/j.cgh.2026.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。